HER2-Negative Breast Cancer’s Therapeutic Market

Date: 22-Apr-2015
HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can cure this disease if detected at the later stages. HER2-Negative Breast Cancer usually occurs to women in the age group of 50 and above. The global cancer market has been forecasted to rise at a CAGR of 6.9% over the period of 2010 to 2016. Maximum cases of breast cancer have been reported in UK along with Germany and Spain. In the years to come US and Japan will be among the top 2 markets for cancer.

To know more about HER2-Negative Breast Cancer one can read the PharmaPoint: HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2023 (http://www.rnrmarketresearch.com/pharmapoint-her2-negative-breast-cancer-global-drug-forecast-and-market-analysis-to-2023-market-report.html .). The report discusses the evolution path of disease management and the impact of drug manufacturers. It discusses in details KOL’s take on latest therapies and strategies for development of drug development. It gives an in-sight into the future of the drug market of HER2-Negative Breast Cancer. This market is expected to grow at a CAGR of 15.5% from $1.45 billion in 2013 to $6.12 billion in 2023. The report covers some of the top players of this market like AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis and GlaxoSmithKline. The report provides a market outlook geography-wise of regions like US, France, Germany, Italy, Spain, Uk, Japan and China. The details covered in this section are forecast of the future, key happenings of the market, along with the opportunity and threat the market poses.

With improved medication and newer drugs being invented the rate of survival for cancer suffering patients has improved considerably. There are lot of drugs under trial and it’s expected that with invention of it there will be an improved remedy to the problem. Palbociclib is one such drug that was in Phase-3 of its trial and the results of the trial are expected sometime in April this year. Novartis and Pfizer have been two of the top chemists and have recorded highest sale of HER2-Negative Breast Cancer drug. All medicines need the authorization of the governing body of the region where the medicine will be marketed. National Institute for Health and Clinical Excellence (NICE) has recommended the National Health Service (NHS) to determine the pricing of the drugs such that the correct price is determined that is in proportion to the benefits the research undertaken.

The report also includes important profiles of drugs such as Abemaciclib (LY2835219), Buparlisib (BKM- 120), Javlor (vinflunine), LEE011, NeuVax (nelipepimut-S/E75), Niraparib (MK4827), NKTR- 102 (etirinotecan pegol), Lynparza (olaparib), Palbociclib (PD-0332991), Talazoparib (BMN 673) and Veliparib (ABT-888). The PharmaPoint: HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2023 provides a view of the global market scenario.